| Old Articles: <Older 3141-3150 Newer> |
|---|
 |
The Motley Fool
September 27, 2006
Michael P. Cecil |
A Drug-Price Avalanche? Wal-Mart shapes the way America buys many products, and its recently announced $4 program for generic prescription drugs may be the harbinger of a major change in prescription-drug sales.   |
The Motley Fool
September 26, 2006
Brian Lawler |
CVT's Looming Date With Destiny A pivotal trial for its lead drug, Ranexa, is nearing completion. Investors, take note. |
The Motley Fool
September 26, 2006
Brian Lawler |
A Savior for Cephalon? The FDA's approval of Fentora comes just in time for the drug company. Investors, take note. |
The Motley Fool
September 26, 2006
Brian Lawler |
GPC's Trial Glee A new platinum-based cancer treatment yields encouraging results. Investors, take note. |
The Motley Fool
September 25, 2006
Brian Lawler |
Merck's Positive Contribution Bad press from Vioxx shouldn't overshadow the company's new offering. Investors, take note. |
Chemistry World
September 22, 2006 |
Altana Sells Off Pharma Division The German pharmaceuticals and chemicals group Altana has sold its entire pharmaceutical business -- Altana Pharma -- to Danish drug company Nycomed. |
The Motley Fool
September 22, 2006
Brian Lawler |
The Truth About Dietary Supplements The real issue here is not about one possibly corrupt supplement company -- it's about customers not knowing that the U.S. supplement industry isn't regulated the way pharmaceutical companies are. |
The Motley Fool
September 22, 2006
Brian Lawler |
Hospira's New Mate Down Under The specialty injectable pharmaceutical announces an acquisition, but the move means adding on a lot more debt. Investors, take note. |
BusinessWeek
October 2, 2006
Gene G. Marcial |
A Shot In The Arm For Cleveland BioLabs Cleveland Clinic Foundation, famous for treating heart ailments and cancer, has joined forces with Cleveland BioLabs, which received exclusive rights to its cancer and molecular genetic technology. |
The Motley Fool
September 21, 2006
Jack Uldrich |
Harris & Harris Looks to Separate New technology could lead to safer, more effective drugs. Because of proprietary reasons, it's unlikely that ENS will be able to publicly announce when Big Pharma companies have licensed its technology, but Harris & Harris investors have reason to be optimistic. |
| <Older 3141-3150 Newer> Return to current articles. |
